Neuromuscular Dysfunction in Experimental Sepsis and Glutamine

Area of Science:

• Neurology
• Critical Care Medicine
• Biochemistry

Background:

• Critical illness polyneuromyopathy develops early in sepsis, preceding clinical symptoms.
• Sepsis-induced metabolic changes render glutamine a conditionally essential amino acid.

Purpose of the Study:

• To evaluate the impact of glutamine supplementation on neuromuscular transmission during the early stages of sepsis.
• To investigate the potential of glutamine in mitigating sepsis-associated neuromuscular dysfunction.

Main Methods:

• Animal model study using male Sprague-Dawley rats.
• Randomized controlled trial with a glutamine-supplemented group and a control group.
• Assessment of compound muscle action potential (CMAP) latency before and 24 hours after cecal ligation and perforation (CLP) surgery.

Main Results:

• Sepsis induction (CLP) led to prolonged CMAP latency in the control group (0.68±0.05 ms to 0.80±0.09 ms).
• Glutamine supplementation significantly attenuated this prolongation, with latency changing from 0.69±0.07 ms to 0.73±0.07 ms (p<0.05).
• Enteral glutamine effectively prevented the increase in CMAP latency observed in the early phase of sepsis.

Conclusions:

• Enteral glutamine administration may prevent neuromuscular dysfunction in the early stages of sepsis.
• Glutamine supplementation shows promise in mitigating sepsis-induced neuromuscular complications.
• Further research is warranted to confirm these findings and explore clinical applications.